contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


vistin-pharma-asa-second-quarter-and-ytd-2025-financial-results

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Vistin Pharma är ett norskt läkemedelsbolag. Bolaget bedriver forskning och utveckling samt vidare produktion av farmaceutiska substanser (API), främst substanserna metformin, kodein fosfat och folkodin. Substanserna används huvudsakligen vid behandling av diabetes. Bolaget är verksamt på global nivå, med störst närvaro på den nordiska marknaden. Vistin Pharma grundades 2015 och har sitt huvudkontor i Oslo.

Vistin Pharma

Oslo, Norway, 15th of August 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the second quarter of 2025. Revenue in the second quarter ended at MNOK 118 compared to ...

Oslo, Norway, 15th of August 2025 Vistin Pharma ASA (VISTN) today announces the financial results for the second quarter of 2025. Revenue in the second quarter ended at MNOK 118 compared to MNOK 106 in Q2 2024. The increase in revenue was driven by 17% higher sales volume. Revenue for first half of 2025 ended at MNOK 233 compared to MNOK 210 YTD last year, an increase of 11%. Second quarter EBITDA ended at MNOK 30 compared to MNOK 27 in Q2 2024, representing 11% increase. EBITDA was positively affected by increased sales volume and continued focus on cost improvements. EBITDA for first half of 2025 ended at MNOK 60 compared to MNOK 48 YTD 2024, an increase of 27%. The net profit ended at MNOK 40.2 (26.8) for the first half of 2025. Cash dividend of NOK 1.25 per share distributed to shareholders in June. The second quarter conference call, which will be held today, 15th of August at 8.30am (CET), will be available via webcast and audio through the following access points: Webcast: <a href="https://www.globenewswire.com/Tracker?data=wJcqfUIJfgX-85BIYZBa43QjBPegVsfvIKyXV97NmxbHHRytOkhfr5BeieVxL5H1zm0elLFdZ9CWb1xFtAP47o-1aTDA0XSXGKU7YGVf7FaLset7VwAXzCZqMXFw3hqHt3zdjzFhH7QFY9U44yUYxNgI2bbjfff-HbgfZ0QwoiQ=">https://edge.media-server.com/mmc/p/vvot47w4</a> Telephone conference (online registration): <a href="https://www.globenewswire.com/Tracker?data=wJcqfUIJfgX-85BIYZBa412zkhNDfOles-y4EAUEBQR9facznA911MUAw2Z6ky3Rm5JzP_AvOXT1c9j1-GLGI-VVx8PtquunyrrWXeln9uP6cG4cU3_yW306pDUPFblcMu65_27EOE47rJcyxrQKvSf6hhvr8RAgcJoOVJh06xdEvOrrlmv__uMnag8E6J5YZ-l1sDMez9wweo41uBRRak8VNHNWW1X-UU-QSsy6oZafzEc8AEJw27GMC8UeDzvDUa0t9zz8oQ23EYIV_ozDdg==">https://register-conf.media-server.com/register/BI65266ce5abba480f9cda4180274c996b</a> The conference call will be held in English. &nbsp;&nbsp; Please find the Q2 report and presentation enclosed. The report will also be made available on <a href="https://www.globenewswire.com/Tracker?data=bowr6rckIILzq-A6TlkM-MYpFnH9plF7qaxKBUKcexE6N4LLbFBKB9VD5llQQ3z19-PNl6umohdWS4W9eohw3VBdBqvHM7Trfk-ZsdLOuhM=">www.vistin.com</a>. ***** For further information, please contact: Alexander Karlsen CFO +47 97 05&nbsp;36 21 <a href="https://www.globenewswire.com/Tracker?data=-Dx5P_4w9Ad8TnqJEblPCe1i0NZJkyb4n7u3B-Z-I7HtZfDpAy7vu5JEgE1AnnNkUJd1mcj2cksFZzKH7W8btEoc3nHrM34gH5zJ2KV8omph5kbGCb4qeXI5_nS_PpXs">alexander.karlsen@vistin.com</a> This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act. &nbsp; Attachments<ul> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/72af1a43-b4d7-4d02-930c-93b2618d1775">Vistin Pharma_Q2_25_presentation_final</a> </li> <li> <a href="https://ml-eu.globenewswire.com/Resource/Download/7ef72883-1af9-499e-809e-d2a4778a0ad6">Vistin Pharma ASA Q2 report 2025_final</a> </li> </ul><img src="https://www.globenewswire.com/newsroom/ti?nf=MTAwMTEyMjkyMyM0MDIxOTgzNjQjMjAxODc1NA==" alt=""> <img src="https://ml-eu.globenewswire.com/media/ODRhYWU2ZWUtYmNiMS00NTE3LWJhMDAtNTAyYjI1NTQyZjA0LTEwMzAzMjctMjAyNS0wOC0xNS1lbg==/tiny/Vistin-Pharma-ASA.png" alt="">

Vistin Pharma ASA: Second quarter and YTD 2025 financial results

USA:s Black Week ledde till överraskande inköp

Måste man arbeta långa dagar? Ekonomen funderar

Uppgångsvecka bakom oss, Tyskland gick vidare med sin megabudget

Finlands ekonomiska tillväxt: ”Varje dag och varje natt tänker jag på dig”

Nedgångsvecka bakom oss, AI-oron når även obligationsmarknaden